Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;13(2):195–210. doi: 10.1111/j.1750-3639.2003.tb00019.x

Changing Patterns in the Neuropathogenesis of HIV During the HAART Era

T D Langford 1, S L Letendre 2, G J Larrea 3, E Masliah 1,3,✉
PMCID: PMC4842209  NIHMSID: NIHMS570554  PMID: 12744473

Abstract

Rapid progress in the development of highly active antiretroviral therapy has changed the observed patterns in HIV encephalitis and AIDS‐related CNS opportunistic infections. Early in the AIDS epidemic, autopsy studies pointed to a high prevalence of these conditions. With the advent of nucleoside reverse transcriptase inhibitors, the prevalence at autopsy of opportunistic infections, such as toxoplasmosis and progressive multifocal leukoencephalopathy, declined while that of HIV encephalitis increased. After the introduction of protease inhibitors, a decline in both HIV encephalitis and CNS opportunistic infections was observed. However, with the increasing resistance of HIV strains to anti‐retrovirals, there has been a resurgence in the frequency of HIV encephalitis and HIV leukoencephalopathy. HIV leukoencephalopathy in AIDS patients failing highly active antiretroviral therapy is characterized by massive infiltration of HIV infected monocytes/macrophages into the brain and extensive white matter destruction. This condition may be attributable to interactions of anti‐retrovirals with cerebrovascular endothelium, astroglial cells and white matter of the brain. These interactions may lead to cerebral ischemia, increased blood‐brain barrier permeability and demyelination. Potential mechanisms of such interactions include alterations in host cell signaling that may result in trophic factor dysregulation and mitochondrial injury. We conclude that despite the initial success of combined anti‐retroviral therapy, more severe forms of HIV encephalitis appear to be emerging as the epidemic matures. Factors that may contribute to this worsening include the prolonged survival of HIV‐infected patients, thereby prolonging the brain's use of increasingly toxic combinations of poorly penetrating drugs in highly antiretroviral‐experienced AIDS patients, and selection of more virulent HIV strains with higher replication rates and greater virulence in neural tissues.

Full Text

The Full Text of this article is available as a PDF (510.2 KB).

References

  • 1. Achim C, Wang R, Miners D, Wiley C (1994) Brain viral burden in HIV infection. J Neuropathol Exp Neurol 53:284–294. [DOI] [PubMed] [Google Scholar]
  • 2. Ammassari A, Cingolani A, Pezzotti P, De Luca DA, Murri R, Giancola ML, Larocca LM, Antinori A (2000) AIDS‐related focal brain lesions in the era of highly active anti‐retroviral therapy. Neurology 55:1194–1200. [DOI] [PubMed] [Google Scholar]
  • 3. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol‐lowering and antioxidant therapy on endothelium‐dependent coronary vasomotion. N Engl J Med 332:488–493. [DOI] [PubMed] [Google Scholar]
  • 4. Aukrust P, Bjornsen S, Lunden B, Otterdal K, Ng EC, Ameln W, Ueland T, Muller F, Solum NO, Brosstad F et al (2000) Persistently elevated levels of von Willebrand factor antigen in HIV infection. Downregulation during highly active antiretroviral therapy. Thromb Haemost 84:183–187. [PubMed] [Google Scholar]
  • 5. Bendayan R, Lee G, Bendayan M (2002) Functional expression and localization of P‐glycoprotein at the blood brain barrier. Microsc Res Tech 57:365–380. [DOI] [PubMed] [Google Scholar]
  • 6. Blum MR, Liao SH, Good SS, de Miranda P (1988) Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 85:189–194. [PubMed] [Google Scholar]
  • 7. Budka H, Wiley C, Kleihues P, Artigas J, Ashbury A, Cho E‐S, Cornblath D (1991) HIV‐associated disease of the nervous system: Review of nomenclature and proposal for neuropathology‐based terminology. Brain Pathol 1:143–152. [DOI] [PubMed] [Google Scholar]
  • 8. Caron M, Auclair M, Vigouroux C, Glorian M, Forest C, Capeau J (2001) The HIV protease inhibitor indinavir impairs sterol regulatory element‐binding protein‐1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50:1378–1388. [DOI] [PubMed] [Google Scholar]
  • 9. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS et al (2000) Antiretroviral therapy in adults: updated recommendations of the International AIDS Society‐USAPanel. JAMA 283:381–390. [DOI] [PubMed] [Google Scholar]
  • 10. Carr A, Cooper DA (2000) Adverse effects of antiretroviral therapy. Lancet 356:1423–1430. [DOI] [PubMed] [Google Scholar]
  • 11. Chariot P, Bourokba N, Brivet F (2002) Mitochondrial DNA and nucleoside toxicity. N Engl J Med 347:216–218; discussion 216–218. [DOI] [PubMed] [Google Scholar]
  • 12. Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwander S, Goebel FD, Glauser M, Antunes F et al (1996) Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 11:39–44. [DOI] [PubMed] [Google Scholar]
  • 13. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB (2000) Pharmacological inhibition of P‐glycoprotein transport enhances the distribution of HIV‐1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655–660. [PubMed] [Google Scholar]
  • 14. Chun TW, Fauci AS (1999) Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A 96:10958–10961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Cordon‐Cardo C, O'Brien JP, Casals D, Rittman‐Grauer L, Biedler JL, Melamed MR, Bertino JR (1989) Multidrug‐resistance gene (P‐glycoprotein) is expressed by endothelial cells at blood‐brain barrier sites. Proc Natl Acad Sci U S A 86:695–698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Cote HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, Ting L, Wong H, Harris M, Harrigan PR, O'Shaughnessy MV et al (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV‐infected patients. N Engl J Med 346:811–820. [DOI] [PubMed] [Google Scholar]
  • 17. Cui L, Locatelli L, Xie MY, Sommadossi JP (1997) Effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC‐12 cells. J Pharmacol Exp Ther 280:1228–1234. [PubMed] [Google Scholar]
  • 18. Dallasta L, Pisarov L, Esplen J, Werley J, Moses A, Nelson J, Achim C (1999) Blood‐brain barrier tight junction disruption in human immunodeficiency virus‐1 encephalitis. Am J Pathol 155:1915–1927. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Darley‐Usmar VM, Hogg N, O'Leary VJ, Wilson MT, Moncada S (1992) The simultaneous generation of superoxide and nitric oxide can initiate lipid peroxidation in human low density lipoprotein. Free Radic Res Commun 17:9–20. [DOI] [PubMed] [Google Scholar]
  • 20. Davies J, Everall I, Weich S, McLaughlin J, Scaravilli F, Lantos P (1997) HIV‐associated brain pathology in the United Kingdom: an epidemiological study. AIDS 11:1145–1150. [DOI] [PubMed] [Google Scholar]
  • 21. De Clercq E (2002) New antiHIV agents and targets. Med Res Rev 22:531–565. [DOI] [PubMed] [Google Scholar]
  • 22. De Clercq E (2002) New developments in antiHIV chemotherapy. Biochim Biophys Acta 1587:258–275. [DOI] [PubMed] [Google Scholar]
  • 23. Demeule M, Jodoin J, Gingras D, Beliveau R (2000) P‐glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 466:219–224. [DOI] [PubMed] [Google Scholar]
  • 24. Deutsch R, Ellis RJ, McCutchan JA, Marcotte TD, Letendre S, Grant I (2001) AIDS‐associated mild neurocognitive impairment is delayed in the era of highly active antiretroviral therapy. AIDS 15:1898–1899. [DOI] [PubMed] [Google Scholar]
  • 25. Dieleman JP, Jambroes M, Gyssens IC, Sturkenboom MC, Stricker BH, Mulder WM, de Wolf F, Weverling GJ, Lange JM, Reiss P et al (2002) Determinants of recurrent toxicity‐driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 16:737–745. [DOI] [PubMed] [Google Scholar]
  • 26. Dore GJ, Correll PK, Li Y, Kaldor JM, Cooper DA, Brew BJ (1999) Changes to AIDS dementia comples in the era of highly active antiretroviral theraphy. AIDS 13:1249–1253. [DOI] [PubMed] [Google Scholar]
  • 27. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J (1999) HIV protease inhibitor ritonavir: a more potent inhibitor of P‐glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57:1147–1152. [DOI] [PubMed] [Google Scholar]
  • 28. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, Atkinson JH, Grant I, Mallory M, Masliah E, Group TH (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. Brain Pathol 9:209–217. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Fenart L, Buee‐Scherrer V, Descamps L, Duhem C, Poul‐lain MG, Cecchelli R, Dehouck MP (1998) Inhibition of P‐glycoprotein:rapid assessment of its implication in blood‐brain barrier integrity and drug transport to the brain by an in vitro model of the blood‐brain barrier. Pharm Res 15:993–1000. [DOI] [PubMed] [Google Scholar]
  • 30. Fischl MA, Richman DD, Grieco MH, Gottlieb MS, Volberding PA, Laskin OL, Leedom JM, Groopman JE, Mild‐van D, Schooley RT et al (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS related complex. Adoubleblind, placebo‐controlled trial. N Engl J Med 317:185–191. [DOI] [PubMed] [Google Scholar]
  • 31. Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, Keet IP, Portegies P (1998) Cerebrospinal‐fluid HIV‐1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 351:1547–1551. [DOI] [PubMed] [Google Scholar]
  • 32. Garrigues A, Escargueil AE, Orlowski S (2002) The multidrug transporter, P‐glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A 99:10347–10352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33. Gartner S (2000) AIDS: HIV infection and dementia. Science 287:602. [DOI] [PubMed] [Google Scholar]
  • 34. Gendelman HE, Zheng J, Coulter CL, Ghorpade A, Che M, Thylin M, Rubocki R, Persidsky Y, Hahn F, Reinhard J, Jr. et al (1998) Suppression of inflammatory neurotoxins by highly active antiretroviral therapy in human immunodeficiency virus‐associated dementia. J Infect Dis 178:1000–1007. [DOI] [PubMed] [Google Scholar]
  • 35. Giner V, Fernandez C, Esteban MJ, Galindo MJ, Forner MJ, Guix J, Redon J (2002) Reversible posterior leukoencephalopathy secondary to indinavir‐induced hypertensive crisis: a case report. Am J Hypertens 15:465–467. [DOI] [PubMed] [Google Scholar]
  • 36. Glynn SL, Yazdanian M (1998) In vitro blood‐brain barrier permeability of nevirapine compared to other HIV anti‐retroviral agents. J Pharm Sci 87:306–310. [DOI] [PubMed] [Google Scholar]
  • 37. Goetz MB, Boscardin WJ, Wiley D, Alkasspooles S (2001) Decreased recovery of CD4 lymphocytes in older HIV‐infected patients beginning highly active antiretroviral therapy. AIDS 15:1576–1579. [DOI] [PubMed] [Google Scholar]
  • 38. Golden PL, Pardridge WM (2000) Brain microvascular P‐glycoprotein and a revised model of multidrug resistance in brain. Cell Mol Neurobiol 20:165–181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Gollapudi S, Gupta S (1990) Human immunodeficiency virus Iinduced expression of Pglycoprotein. Biochem Biophys Res Commun 171:1002–1007. [DOI] [PubMed] [Google Scholar]
  • 40. Goodkin K, Wilkie FL, Concha M, Hinkin CH, Symes S, Baldewicz TT, Asthana D, Fujimura RK, Lee D, van Zuilen MH et al (2001) Aging and neuro‐AIDS conditions and the changing spectrum of HIV‐1‐associated morbidity and mortality. J Clin Epidemiol 54 Suppl 1:S35–43. [DOI] [PubMed] [Google Scholar]
  • 41. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427. [DOI] [PubMed] [Google Scholar]
  • 42. Gray F, Adle‐Biassette H, Chretien F, Lorin de la Grand‐maison G, Force G, Keohane C (2001) Neuropathology and neurodegeneration in human immunodeficiency virus infection. Pathogenesis of HIV‐induced lesions of the brain, correlations with HIV‐associated disorders and modifications according to treatments. Clin Neuropathol 20:146–155. [PubMed] [Google Scholar]
  • 43. Gray F, Belec L, Keohane C, De Truchis P, Clair B, Durigon M, Sobel A, Gherardi R (1994) Zidovudine therapy and HIV encephalitis: a 10‐year neuropathological survey. AIDS 8:489–493. [DOI] [PubMed] [Google Scholar]
  • 44. Harrold SM, Wang G, McMahon DK, Riddler SA, Mellors JW, Becker JT, Caldararo R, Reinhart TA, Achim CL, Wiley CA (2002) Recovery of replication‐competent HIV type 1‐infected circulating monocytes from individuals receiving antiretroviral therapy. AIDS Res Hum Retro-viruses 18:427–434. [DOI] [PubMed] [Google Scholar]
  • 45. Hoffmann C, Jaeger H (2001) Cardiology and AIDS‐HAART and the consequences. Ann NY Acad Sci 946:130–144. [DOI] [PubMed] [Google Scholar]
  • 46. Hong M, Schlichter L, Bendayan R (2001) A novel zidovudine uptake system in microglia. J Pharmacol Exp Ther 296:141–149. [PubMed] [Google Scholar]
  • 47. Irlbeck D, Stanhope, M.J. , Douady, C. , Amrine, H.M. , Melby, T. , McCLernon, D.R. , Lanier, E.R. Phylogenetic analyses of HIV‐1 from an AIDS Dementia patient suggest compartmentalized evolution in the mid‐frontal gyrus of the brain. XI International Workshop on Drug Resistance and Treatment Strategies. Seville, Spain 2002. [Google Scholar]
  • 48. Jamieson DG, Usher DC, Rader DJ, Lavi E (1995) Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. Apotential role for endothelial cells in lesion formation. Am J Pathol 147:1567–1574. [PMC free article] [PubMed] [Google Scholar]
  • 49. Janssen RS, Nwanyanwu OC, Selik RM, Stehr‐Green JK (1992) Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 42:1472–1476. [DOI] [PubMed] [Google Scholar]
  • 50. Jellinger KA, Setinek U, Drlicek M, Bohm G, Steurer A, Lintner F (2000) Neuropathology and general autopsy findings in AIDS during the last 15 years. Acta Neuropathol (Berl) 100:213–220. [DOI] [PubMed] [Google Scholar]
  • 51. Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA, Back DJ (2001) P‐Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance AIDS 15:1353–1358. [DOI] [PubMed] [Google Scholar]
  • 52. Jones S, Klotman ME (2001) Impact of genotypic resistance testing on physician selection of antiretroviral therapy. J Hum Virol 4:214–216. [PubMed] [Google Scholar]
  • 53. Jorajuria S, Clayette P, Dereuddre‐Bosquet N, Larghero J, Thiebot H, Neildez O, Vaslin B, Le Grand R, Dormont D (2000) [Evaluation of the effect of early and massive tritherapy on the expression of cellular factors potentially implicated in antiretroviral therapy resistance]. Pathol Biol (Paris) 48:490–494. [PubMed] [Google Scholar]
  • 54. Jordan‐Sciutto KL, Wang G, Murphey‐Corb M, Wiley CA (2002) Cell cycle proteins exhibit altered expression patterns in lentiviral‐associated encephalitis. J Neurosci 22:2185–2195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Kim AE, Dintaman JM, Waddell DS, Silverman JA (1998) Saquinavir, an HIV protease inhibitor, is transported by Pglycoprotein. J Pharmacol Exp Ther 286:1439–1445. [PubMed] [Google Scholar]
  • 56. Kim B, Lyons TM, Parada JP, Uphold CR, Yarnold PR, Hounshell JB, Sipler AM, Goetz MB, DeHovitz JA, Weinstein RA et al (2001) HIV‐related Pneumocystis carinii pneumonia in older patients hospitalized in the early HAARTera. J Gen Intern Med 16:583–589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR (1998) The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV‐1 protease inhibitors. J Clin Invest 101:289–294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS (2002) Differences in therapeutic indexes of combination metronomic chemotherapy and an anti‐VEGFR‐2 antibody in multidrug‐resistant human breast cancer xenografts. Clin Cancer Res 8:221–232. [PubMed] [Google Scholar]
  • 59. Klint P, Kanda S, Kloog Y, Claesson‐Welsh L (1999) Contribution of Src and Ras pathways in FGF‐2 induced endothelial cell differentiation. Oncogene 18:3354–3364. [DOI] [PubMed] [Google Scholar]
  • 60. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, Elner SG, Strieter RM (1992) Interleukin‐8 as a macrophage‐derived mediator of angiogenesis. Science 258:1798–1801. [DOI] [PubMed] [Google Scholar]
  • 61. Kusdra L, McGuire D, Pulliam L (2002) Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV‐associated dementia. AIDS 16:31–38. [DOI] [PubMed] [Google Scholar]
  • 62. Lackner A, Smith M, Munn R, Martfeld D, Gardner M, Marx P, Dandekar S (1991) Localization of simian immunodeficiency virus in the central nervous system of rhesus monkeys. Am J Pathol 139:609–621. [PMC free article] [PubMed] [Google Scholar]
  • 63. Langford D, Masliah E (2001) Crosstalk between components of the blood brain barrier and cells of the CNS in microglial activation in AIDS. Brain Pathol 11:306–312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T et al (2002) Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16:1019–1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65. Lanier ER, Sturge G, McClernon D, Brown S, Halman M, Sacktor N, McArthur J, Atkinson JH, Clifford D, Price RW et al (2001) HIV‐1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS 15:747–751. [DOI] [PubMed] [Google Scholar]
  • 66. Lee CG, Gottesman MM (1998) HIV‐1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 101:287–288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67. Lee TH, Avraham H, Lee SH, Avraham S (2002) Vascular endothelial growth factor modulates neutrophil transendothelial migration via up‐regulation of interleukin‐8 in human brain microvascular endothelial cells. J Biol Chem 277:10445–10451. [DOI] [PubMed] [Google Scholar]
  • 68. Li S, Couet J, Lisanti MP (1996) Src tyrosine kinases, Galpha subunits, and H‐Ras share a common membrane‐anchored scaffolding protein, caveolin. Caveolin binding negatively regulates the auto‐activation of Src tyrosine kinases. J Biol Chem 271:29182–29190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Li S, Okamoto T, Chun M, Sargiacomo M, Casanova JE, Hansen SH, Nishimoto I, Lisanti MP (1995) Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chem 270:15693–15701. [DOI] [PubMed] [Google Scholar]
  • 70. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, Sturley SL (2001) HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitorinduced hyperlipidemia. Nat Med 7:1327–1331. [DOI] [PubMed] [Google Scholar]
  • 71. Limoges J, Poluektova L, Ratanasuwan W, Rasmussen J, Zelivyanskaya M, McClernon DR, Lanier ER, Gendelman HE, Persidsky Y (2001) The efficacy of potent anti‐retro‐viral drug combinations tested in a murine model of HIV‐1 encephalitis. Virology 281:21–34. [DOI] [PubMed] [Google Scholar]
  • 72. Liu P, Ying Y, Anderson RG (1997) Platelet‐derived growth factor activates mitogen‐activated protein kinase in isolated caveolae. Proc Natl Acad Sci U S A 94:13666–13670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S (2000) Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol 6 Suppl 1:S70–81. [PubMed] [Google Scholar]
  • 74. Lucia MB, Rutella S, Leone G, Vella S, Cauda R (2001) HIV‐protease inhibitors contribute to P‐glycoprotein efflux function defect in peripheral blood lymphocytes from HIV‐positive patients receiving HAART. J Acquir Immune Defic Syndr 27:321–330. [DOI] [PubMed] [Google Scholar]
  • 75. Maehlen J, Dunlop O, Liestol K, Dobloug JH, Goplen AK, Torvik A (1995) Changing incidence of HIV‐induced brain lesions in Oslo, 1983–1994: effects of zidovudine treatment. AIDS 9:1165–1169. [PubMed] [Google Scholar]
  • 76. Mahieux R, Lambert PF, Agbottah E, Halanski MA, Deng L, Kashanchi F, Brady JN (2001) Cell cycle regulation of human interleukin‐8 gene expression by the human immunodeficiency virus type 1 Tat protein. J Virol 75:1736–1743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77. Martinez E, Mocroft A, Garcia‐Viejo MA, Perez‐Cuevas JB, Blanco JL, Mallolas J, Bianchi L, Conget I, Blanch J, Phillips A et al (2001) Risk of lipodystrophy in HIV‐1‐infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357:592–598. [DOI] [PubMed] [Google Scholar]
  • 78. Masliah E, Achim C, Ge N, DeTeresa R, Terry R, Wiley C (1992) Spectrum of human immunodeficiency virusassociated neocortical damage. Ann Neurol 32:321–329. [DOI] [PubMed] [Google Scholar]
  • 79. Masliah E, DeTeresa R, Mallory M, Hansen L (2000) Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14:69–74. [DOI] [PubMed] [Google Scholar]
  • 80. Masliah E, Ge N, Achim C, DeTeresa R, Wiley C (1996) Patterns of neurodegeneration in HIV encephalitis. NeuroAIDS 1:161–173. [DOI] [PubMed] [Google Scholar]
  • 81. Masliah E, Heaton R, Marcotte T, Ellis R, Wiley C, Mallory M, Achim C, McCutchan A, Nelson J, Atkinson H et al (1997) Dendritic injury is a pathological substrate for human immunodefficiency virus‐related cognitive disorders. Ann Neurol 42:963–972. [DOI] [PubMed] [Google Scholar]
  • 82. McArthur J, Hoover D, Bacellar H, Miller E, Cohen B, Becker J, Graham N, McArthur J, Selnes O, Jacobson L et al (1993) Dementia in AIDS patients: incidence and risk factors. Neurology 43:2245–2252. [DOI] [PubMed] [Google Scholar]
  • 83. Mineo C, James GL, Smart EJ, Anderson RG (1996) Localization of epidermal growth factor‐stimulated Ras/Raf‐1 interaction to caveolae membrane. J Biol Chem 271:11930–11935. [DOI] [PubMed] [Google Scholar]
  • 84. Morris L, Silber E, Sonnenberg P, Eintracht S, Nyoka S, Lyons S, Saffer D, Koornhof H, Martin D (1998) High human immunodeficiency virus type 1 RNA load in the cerebrospinal fluid from patients with lymphocytic meningitis. J Inf Dis 177:473–476. [DOI] [PubMed] [Google Scholar]
  • 85. Moyle G (2000) Clinical manifestations and management of antiretroviral nucleoside analog‐related mitochondrial toxicity. Clin Ther 22:911–936; discussion 898. [DOI] [PubMed] [Google Scholar]
  • 86. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M (2000) Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23:35–43. [DOI] [PubMed] [Google Scholar]
  • 87. Nguyen AT, Gagnon A, Angel JB, Sorisky A (2000) Ritonavir increases the level of active ADD‐1/SREBP‐1 protein during adipogenesis. AIDS 14:2467–2473. [DOI] [PubMed] [Google Scholar]
  • 88. Nottet H, Persidsky Y, Sasseville V, Nukuna A, Bock P, Zhai Q, Sharer L, McComb R, Swindells S, Soderland C et al (1996) Mechanisms for the transendothelial migration of HIV‐1‐infected monocytes into brain. J Immunol 156:1284–1295. [PubMed] [Google Scholar]
  • 89. O'Driscoll G, Green D, Taylor RR (1997) Simvastatin, an HMG‐coenzyme Areductase inhibitor, improves endothelial function within 1 month. Circulation 95:1126–1131. [DOI] [PubMed] [Google Scholar]
  • 90. Ohara Y, Peterson TE, Harrison DG (1993) Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 91:2546–2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 91. Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S, Couet J, Lisanti MP, Ishikawa Y (1997) Caveolin interaction with protein kinase C. Isoenzyme‐dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 272:33416–33421. [DOI] [PubMed] [Google Scholar]
  • 92. Orandle MS, MacLean AG, Sasseville VG, Alvarez X, Lackner AA (2002) Enhanced expression of proinflammatory cytokines in the central nervous system is associated with neuroinvasion by simian immunodeficiency virus and the development of encephalitis. J Virol 76:5797–5802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 93. Pan‐Zhou XR, Cui L, Zhou XJ, Sommadossi JP, Darley‐Usmar VM (2000) Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells. Antimicrob Agents Chemother 44:496–503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 94. Persidsky Y, Ghorpade A, Rasmussen J, Limoges J, Liu X, Stins M, Fiala M, Way D, Kim K, Witte M et al (1999) Microglial and astrocyte chemokines regulate monocyte migration through the blood‐brain barrier in human immunodeficiency virus‐1 encephalitis. Am J Pathol 155:1599–1611. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 95. Persidsky Y, Stins M, Way D, Witte M, Weinand M, Kim K, Bock P, Gendelman H, Fiala M (1997) Amodel of monocyte migration through the blood‐brain barrier during HIV‐1 encephalitis. J Immunol 158:3499–3510. [PubMed] [Google Scholar]
  • 96. Pohlman TH, Harlan JM (2000) Adaptive responses of the endothelium to stress. J Surg Res 89:85–119. [DOI] [PubMed] [Google Scholar]
  • 97. Power C, Gill MJ, Johnson RT (2002) Progress in clinical neurosciences: the neuropathogenesis of HIV infection: host‐virus interaction and the impact of therapy. Can J Neurol Sci 29:19–32. [DOI] [PubMed] [Google Scholar]
  • 98. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ, Deeks SG (2001) Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15:1251–1259. [DOI] [PubMed] [Google Scholar]
  • 99. Rader DJ, Dugi KA (2000) The endothelium and lipoproteins: insights from recent cell biology and animal studies. Semin Thromb Hemost 26:521–528. [DOI] [PubMed] [Google Scholar]
  • 100. Raulin J (2002) Human immunodeficiency virus and host cell lipids. Interesting pathways in research for a new HIV therapy. Prog Lipid Res 41:27–65. [DOI] [PubMed] [Google Scholar]
  • 101. Resnick L, Berger J, Shapshak P, Tourtellotte W (1988) Early penetration of the blood‐brain‐barrier by HIV. Neurology 38:9–14. [DOI] [PubMed] [Google Scholar]
  • 102. Sacktor N, Lyles RH, Skolasky R, Kleeberger C, Selnes OA, Miller EN, Becker JT, Cohen B, McArthur JC (2001) HIV‐associated neurologic disease incidence changes: Multicenter AIDS Cohort Study, 1990–1998. Neurology 56:257–260. [DOI] [PubMed] [Google Scholar]
  • 103. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K et al (2002) HIV‐associated cognitive impairment before and after the advent of combination therapy. J Neurovirol 8:136–142. [DOI] [PubMed] [Google Scholar]
  • 104. Salcedo R, Wasserman K, Young HA, Grimm MC, Howard OM, Anver MR, Kleinman HK, Murphy WJ, Oppenheim JJ (1999) Vascular endothelial growth factor and basic fibroblast growth factor induce expression of CXCR4 on human endothelial cells: In vivo neurovascularization induced by stromal‐derived factor‐1alpha. Am J Pathol 154:1125–1135. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 105. Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G (2002) Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromalderived factor‐1. Blood 99:2703–2711. [DOI] [PubMed] [Google Scholar]
  • 106. Shelburne SA, 3rd , Hamill RJ, Rodriguez‐Barradas MC, Greenberg SB, Atmar RL, Musher DW, Gathe JC, Jr. , Visnegarwala F, Trautner BW (2002) Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 81:213–227. [DOI] [PubMed] [Google Scholar]
  • 107. Shi B, De Girolami U, He J, Wang S, Lorenzo A, Busciglio J, Gabuzda D (1996) Apoptosis induced by HIV‐1 infection of the central nervous system. J Clin Invest 98:1979–1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Smith KY (2002) Selected metabolic and morphologic complications associated with highly active antiretroviral therapy. J Infect Dis 185 Suppl 2:S123–127. [DOI] [PubMed] [Google Scholar]
  • 109. Sobue K, Yamamoto N, Yoneda K, Hodgson M, Yamashiro K, Tsuruoka N, Katsuya H, Miura Y, Asai K, Kato T (1999) Induction of bloodbrain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res 35:155–164. [DOI] [PubMed] [Google Scholar]
  • 110. Sporer B, Koedel U, Paul R, Kohleisen B, Erfle V, Fontana A, Pfister H (2000) Human immunodeficiency virus type‐1 Nef protein induces blood‐brain barrier disruption in the rat: role of matrix metalloproteinase‐9. J Neuroimmunol 102:125–130. [DOI] [PubMed] [Google Scholar]
  • 111. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM (2001) Use of human immunodeficiency virus‐1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104:257–262. [DOI] [PubMed] [Google Scholar]
  • 112. Steinberg D (1991) Antioxidants and atherosclerosis. Acurrent assessment. Circulation 84:1420–1425. [DOI] [PubMed] [Google Scholar]
  • 113. Stern Y, McDermott MP, Albert S, Palumbo D, Selnes OA, McArthur J, Sacktor N, Schifitto G, Kieburtz K, Epstein L et al (2001) Factors associated with incident human immunodeficiency virus‐dementia. Arch Neurol 58:473–479. [DOI] [PubMed] [Google Scholar]
  • 114. Strelow LI, Watry DD, Fox HS, Nelson JA (1998) Efficient infection of brain microvascular endothelial cells by an in vivo‐selected neuroinvasive SIVmac variant. J Neurovirol 4:269–280. [DOI] [PubMed] [Google Scholar]
  • 115. Suarez S, Baril L, Stankoff B, Khellaf M, Dubois B, Lubetzki C, Bricaire F, Hauw JJ (2001) Outcome of patients with HIV‐1‐related cognitive impairment on highly active antiretroviral therapy. AIDS 15:195–200. [DOI] [PubMed] [Google Scholar]
  • 116. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC (1987) Cellular localization of the mul‐tidrug‐resistance gene product P‐glycoprotein in normal human tissues. Proc Natl Acad Sci U S A 84:7735–7738. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 117. Turriziani O, Antonelli G, Dianzani F (2000) Cellular factors involved in the induction of resistance of HIV to anti‐retroviral agents. Int J Antimicrob Agents 16:353–356. [DOI] [PubMed] [Google Scholar]
  • 118. van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner‐Foisy ML, Sommadossi JP, Burger DM, Lange JM, Hoetelmans RM et al (2000) Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low‐dose ritonavir. AIDS 14:1187–1194. [DOI] [PubMed] [Google Scholar]
  • 119. Wartenberg M, Donmez F, Ling FC, Acker H, Hescheler J, Sauer H (2001) Tumor‐induced angiogenesis studied in confrontation cultures of multicellular tumor spheroids and embryoid bodies grown from pluripotent embryonic stem cells. Faseb J 15:995–1005. [DOI] [PubMed] [Google Scholar]
  • 120. White DA, Heaton RK, Monsch AU (1995) Neuropsychological studies of asymptomatic human immunodeficiency virus‐type‐1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1:304–315. [DOI] [PubMed] [Google Scholar]
  • 121. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, Jeang KT (2000) Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV‐1. Proc Natl Acad Sci U S A 97:11466–11471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 122. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA et al (2002) Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society‐USA Panel. JAMA 288:222–235. [DOI] [PubMed] [Google Scholar]
  • 123. Yozviak JL, Doerfler RE, Woodward WC (2002) Resuppression of virus load after interruption in treatment with nevirapine and 2 nucleoside reverse‐transcriptase inhibitors. Clin Infect Dis 34:547–550. [DOI] [PubMed] [Google Scholar]
  • 124. Zaera MG, Miro O, Pedrol E, Soler A, Picon M, Cardellach F, Casademont J, Nunes V (2001) Mitochondrial involvement in antiretroviral therapy‐related lipodystrophy. AIDS 15:1643–1651. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES